Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy

被引：0
|
作者：
Andrea Katharina Lindner
Felizian Lackner
Piotr Tymoszuk
Dominik Andreas Barth
Andreas Seeber
Florian Kocher
Bettina Toth
Margarethe Hochleitner
Martin Pichler
Renate Pichler
机构：
[1] Medical University of Innsbruck,Department of Urology, Comprehensive Cancer Center Innsbruck
[2] Data Analytics As a Service Tirol,Division of Oncology, Department of Internal Medicine
[3] Medical University of Graz,Department of Hematology and Oncology, Comprehensive Cancer Center Innsbruck
[4] Medical University of Innsbruck,Department of Gynecological Endocrinology and Reproductive Medicine
[5] Medical University Innsbruck,Department of Internal Medicine, Gender Medicine Unit
[6] Medical University of Innsbruck,Translational Oncology
[7] University Hospital of Augsburg,undefined
来源：
Biology of Sex Differences | / 14卷
关键词：
Metastatic urothelial carcinoma; Immunotherapy; Overall survival; Sex hormones; Gonadotropins; Prognostic; Biomarkers;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Urothelial carcinoma (UC) presents as aggressive disease with a greater incidence in men, yet a more aggressive course of disease in women. Patients with metastatic UC receive a chemotherapy regimen as the gold standard, based on an included platin substance. In the case of having contraindications to chemotherapy, checkpoint immunotherapy, priming the immune system to the tumor, is the treatment of choice. Furthermore, immunotherapy is used as second line therapy in progressive disease after chemotherapy and as maintenance therapy in stable tumor conditions after completing the chemotherapy regimen.
引用
收藏
相关论文
共 50 条
  • [21] Immune checkpoint inhibitors for urothelial carcinoma
    Albertsen, Peter
    BJU INTERNATIONAL, 2023, 132 (01) : 3 - 3
  • [22] Immune checkpoint inhibitors for urothelial carcinoma
    Kim, Hyung Suk
    Seo, Ho Kyung
    INVESTIGATIVE AND CLINICAL UROLOGY, 2018, 59 (05) : 285 - 296
  • [23] Maintenance therapy in patients with metastatic urothelial carcinoma
    Kondoh, C.
    ANNALS OF ONCOLOGY, 2024, 35 : S1304 - S1304
  • [24] A Review of Immune Checkpoint Inhibitors for the Management of Locally Advanced or Metastatic Urothelial Carcinoma
    Hanna, Kirollos S.
    PHARMACOTHERAPY, 2017, 37 (11): : 1391 - 1405
  • [25] Local treatment on the outcome of immune-checkpoint inhibitors in metastatic urothelial carcinoma
    Maldonado, J.
    Morales Barrera, R.
    Vidal, N.
    Feltes, N.
    Domenech, M.
    Puente, J.
    Figols, M.
    Gonzalez, M.
    Lozano, F.
    Lopez, H.
    Gallardo, E.
    Moreno, D.
    Suarez, C.
    Morote, J.
    Carles, J.
    Giralt, J.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S637 - S638
  • [26] Immune Checkpoint Inhibition in Metastatic Urothelial Cancer
    Powles, Tom
    Smith, Kate
    Stenzl, Arnulf
    Bedke, Jens
    EUROPEAN UROLOGY, 2017, 72 (04) : 477 - 481
  • [27] Immune Checkpoint Blockade in Metastatic Urothelial Cancer
    Balar, Arjun Vasant
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) : 2109 - +
  • [28] Validation of the VIO prognostic index in patients with metastatic urothelial carcinoma treated with immune-checkpoint inhibitors
    Morales Barrera, R.
    Matos, I.
    Gonzalez, M.
    Suarez, C.
    Ros, J.
    Valverde, C.
    Fernandez, C.
    Hierro, C.
    Serra, E.
    Mateo, J.
    Gutierrez, S.
    Martin Liberal, J.
    Quintana, A.
    Dienstmann, R.
    Serrano, C.
    Garralda, E.
    Carles, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 369 - +
  • [29] Immunological correlates of response to immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts)
    Tzeng, Alice
    Diaz-Montero, C. Marcela
    Rayman, Patricia A.
    Kim, Jin Sub
    Pavicic, Paul G.
    Finke, James
    Barata, Pedro C.
    Lamenza, Marcelo
    Devonshire, Sarah
    Schach, Kim
    Emamekhoo, Hamid
    Ernstoff, Marc S.
    Hoimes, Christopher J.
    Rini, Brian I.
    Garcia, Jorge A.
    Gilligan, Timothy D.
    Ornstein, Moshe Chaim
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [30] Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure
    Park, Joo-Hwan
    Park, Inkeun
    Kim, In-Ho
    Hur, Joon Young
    Hwang, Inhwan
    Kim, Chan
    Kim, Hyo-Jeong
    Maeng, Chi Hoon
    Park, Kwonoh
    Lee, Min-Young
    Lee, Hyo Jin
    Jung, Joo Young
    Keam, Bhumsuk
    Park, Se Hoon
    Lee, Jae Lyun
    CURRENT PROBLEMS IN CANCER, 2022, 46 (03)
12345